关键词：宫颈癌；癌细胞；异常生长；宫颈组织；HPV感染
摘 要：Cervical cancer is characterized by the abnormal growth of cancerous cells in the tissues of the cervix. The disease manifests as either squamous cell carcinoma or adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells filled with mucus and other fluids. Squamous cell carcinoma is the dominant subtype of cervical cancer, affecting about nine out of 10 cervical cancer patients. The disease is asymptomatic in the early stages. The signs and symptoms in the late stages include abnormal vaginal bleeding, unusual vaginal discharge, and pelvic pain. HPV infections are the most common cause of cervical cancer, globally. The incidence of the disease is higher in less developed regions such as Africa, Latin America, and the Caribbean compared to North America and Oceania.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Risk factors

Signs and symptoms

Screening

Diagnosis

Staging

Treatment

Epidemiology

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: Market segmentation by application

Global prophylactic vaccines market

Global therapeutic drugs market

PART 08: Market segmentation by type of therapy

Global cervical cancer therapeutics market by type of

therapy

Chemotherapy

Targeted therapy

HPV vaccines

PART 09: Geographical segmentation

PART 10: Key brand analysis

Comparative study between Gardasil, Gardasil 9, and

Cervarix

PART 11: Pipeline portfolio

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

Competitive scenario

Market analysis 2014

Other prominent vendors

PART 18: Key vendor analysis

GSK

F. Hoffmann-La Roche

Merck

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio